12-amino-N-[(2S,3S,4R)-3,4-dihydroxy-2-[(2S,3R,4S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]dodecanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 12-amino-N-[(2S,3S,4R)-3,4-dihydroxy-2-[(2S,3R,4S,5R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]dodecanamide
• 化学式: C₃₆H₇₂N₂O₉
• 分子量: 677.0
• InChiKey: FYBNWCSYHAZPKC-LIZBZZBESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  47
• 可旋转键数：
  30
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  195
• 氢给体数：
  8
• 氢受体数：
  10

文献信息

• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PROPHYLACTIC TREATMENT OF BACTERIAL SUPERINFECTIONS POST-INFLUENZA WITH INVARIANT NKT CELL AGONISTS
  申请人：INSERM - Institut National de la Santé et de la Recherche Médicale

  公开号：EP2903622A1

  公开（公告）日：2015-08-12
• ACTIVATION OF INKT CELLS
  申请人：INSERM - Institut National de la Santé et de la Recherche Médicale

  公开号：EP2958595A1

  公开（公告）日：2015-12-30
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3104864A1

  公开（公告）日：2016-12-21
• [EN] METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PROPHYLACTIC TREATMENT OF BACTERIAL SUPERINFECTIONS POST-INFLUENZA WITH INVARIANT NKT CELL AGONISTS<br/>[FR] MÉTHODES ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT PROPHYLACTIQUE DES SURINFECTIONS BACTÉRIENNES POST-GRIPPALES PAR DES AGONISTES DE CELLULES NKT INVARIANTS
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2014053482A1

  公开（公告）日：2014-04-10

  The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with iNKT cell agonists.
• [EN] ACTIVATION OF INKT CELLS<br/>[FR] ACTIVATION DE CELLULES INKT
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2014128225A1

  公开（公告）日：2014-08-28

  The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells.